Pharmaceutical Representative Training

OCTOBER 9, 2024

Introduction Every sales professional has experienced deals collapsing at the last minute due to objections from prospects. In the competitive world of pharmaceutical sales, effectively handling customer objections is crucial for success. Enhance your pharmaceutical sales skills by learning to navigate objections.

Sales 52

Sales Pharma Pharmaceutical Sales Prospecting 52

European Pharmaceutical Review

NOVEMBER 25, 2022

GlobalData’s report showed LY03010 is expected to launch in the US in 2024. If successful, the drug is forecasted to reach sales of $63.5 Thus, LY03010 could be more convenient to administer and improve patient compliance by optimising the initial dosing regimen, while ensuring efficacy and safety.

Competition 105

Competition Food and Drug Administration Pharma Food 105

European Pharmaceutical Review

NOVEMBER 2, 2023

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Sustainable biosimilar competition in Europe: can it be achieved? “We

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Safety 98

Nixon Gwilt Law

JUNE 24, 2024

The Digital Therapeutics Alliance Summit 2024 , held in Washington, D.C., Companies that proactively address these aspects create a foundation for sustainable growth and competitive advantage in the digital health ecosystem.

FDA 52

FDA Education Healthcare Healthcare 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

OCTOBER 28, 2022

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 billion and $812 million in 2028.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52